World Health Organization Sounds Concern Over Severe Lack of Weight-Loss Medications
Under one in 10 individuals that would benefit from GLP-1 drugs such as Wegovy are able to get them, caution the global health agency as it issues its inaugural guidance on the therapies.
Given over a billion individuals worldwide now obese, it is urging more widespread and fairer access to GLP-1 medication.
Per forecasts, more than two billion are projected to be living with obesity by 2030 without intervention.
"Our latest guidance affirms that excess weight is a long-term condition that can be managed with holistic and continuous care," said the agency's head Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are major hurdles to universal access to the injections that can aid individuals in losing significant weight, explains the organization.
GLP-1 Therapy Scarcity
Even in the current best projected scenario, the production of such drugs might only reach around 100 million people – less than 10% of eligible patients, as stated by the health organization.
The guideline encourages nations and manufacturers to expand availability, through measures including patent sharing.
Exclusive production rights on a key compound – the primary component of a leading brand – is due to expire in a number of nations in 2026.
How Weight-Loss Drugs Operate
These medications imitate a natural hormone to delay gastric emptying, reduce hunger and boost satiety so users eat less.
Individuals typically begin shedding pounds in the initial weeks of commencing the regular doses.
Evidence indicates patients may see weight return within a year of stopping the drug, as their normal food cravings come back.
To be carrying excess weight increases your likelihood for contracting health problems, like type 2 diabetes, cardiovascular issues, stroke, and specific cancers.
Excess weight concerns individuals in all nations and was associated with millions of fatalities worldwide in 2024, according to the health agency.
